Jacobs Levy Equity Management Inc. Invests $1.55 Million in Emergent BioSolutions Inc. (NYSE:EBS)

Jacobs Levy Equity Management Inc. acquired a new position in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 185,317 shares of the biopharmaceutical company's stock, valued at approximately $1,547,000. Jacobs Levy Equity Management Inc. owned approximately 0.34% of Emergent BioSolutions at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of EBS. Tidal Investments LLC bought a new stake in Emergent BioSolutions during the 1st quarter worth about $34,000. CWM LLC increased its holdings in shares of Emergent BioSolutions by 32,706.7% in the second quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 4,906 shares in the last quarter. Meeder Asset Management Inc. bought a new position in Emergent BioSolutions in the 2nd quarter worth approximately $41,000. Price T Rowe Associates Inc. MD lifted its holdings in Emergent BioSolutions by 22.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 23,943 shares of the biopharmaceutical company's stock worth $61,000 after buying an additional 4,409 shares in the last quarter. Finally, Verus Capital Partners LLC acquired a new stake in shares of Emergent BioSolutions in the 2nd quarter valued at $68,000. Institutional investors own 78.40% of the company's stock.

Emergent BioSolutions Stock Down 1.0 %

Shares of NYSE:EBS traded down $0.09 during midday trading on Monday, reaching $8.92. 644,320 shares of the company were exchanged, compared to its average volume of 3,227,347. The stock has a fifty day simple moving average of $9.38 and a two-hundred day simple moving average of $8.59. Emergent BioSolutions Inc. has a fifty-two week low of $1.42 and a fifty-two week high of $15.10. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30.

Analysts Set New Price Targets

EBS has been the topic of several recent research reports. Benchmark raised their price target on Emergent BioSolutions from $8.00 to $12.00 and gave the company a "buy" rating in a report on Thursday, November 7th. StockNews.com cut shares of Emergent BioSolutions from a "buy" rating to a "hold" rating in a research report on Wednesday, November 20th. Finally, Rodman & Renshaw restated a "buy" rating and issued a $16.00 price objective on shares of Emergent BioSolutions in a report on Friday, September 13th.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.